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Introduction
Breast cancer continues to be the most common cancer 
diagnosed and the leading cause of cancer-related death 
in women worldwide. In North America it has been 
estimated that one woman out of nine will be diagnosed 
with breast cancer in her lifetime and that one in four 
among them will die from the disease [1]. As with other 
cancers, the combination of genetic and epigenetic 
alterations is fundamental in the genesis of breast cancer 
[2]. As the result of multiple alterations, mammary cancer 
progresses through multiple stages in a multistep process 
that drives normal breast cells into highly malignant cells. 
Th  e resulting tumor cells can then invade through 
surrounding tissues and metastasize to distal organs, 
particularly to bones, brain, liver, and lungs [3].
Th   e majority of breast cancers are carcinomas of ductal 
origin since they arise from epithelial cells lining the 
mammary ducts. Th  e pathogenesis involves an initial 
benign intraductal hyperplasia, which progresses through 
cellular atypia (atypical hyperplasia) and occlusion of the 
duct (ductal carcinoma in situ). Th  is later step can be 
followed by locally invasive carcinoma and subsequent 
metastasis to secondary sites [4]. Th  e acquired invasive 
properties include enhanced migratory behavior and the 
capacity of the tumor cells to breach the mammary 
basement membrane (BM), the dense matrix surrounding 
tumors and the blood vessel walls [5]. All of these 
processes involve dynamic adhesion of the tumor cell to 
extracellular matrices (ECMs) through integrins, a major 
family of α/β heterodimeric cell surface receptors [6].
Th  e integrin family contains, in mammals, 18 α-
subunits and eight β-subunits that form 24 distinct 
receptors with speciﬁ  c tissue distribution and that appear 
to have speciﬁ  c and nonredundant functions as shown by 
their speciﬁ  city for ECM ligands and knockout mouse 
phenotypes [7]. Th  e primary function of the integrin 
family is to mediate cell–cell and cell–matrix adhesion. 
Furthermore, the binding of ECM components such as 
ﬁ  bronectin, laminin, proteoglycans and collagen to inte-
grins leads to the recruitment of numerous adaptor and 
signaling proteins to the cytoplasmic tails of the integrin 
β-subunits, forming adhesion protein complexes [8] that 
initiate signaling cascades promoting cell polarity, motility, 
diﬀ  erentiation, proliferation and survival [9]. Accordingly, 
when overexpressed in tumor cells, integrins contribute 
to cancer progression and metastasis by increasing tumor 
cell migration, invasion, proliferation and survival as well 
as tumor angiogenesis [6,10].
Integrin heterodimers are present on the cell surface in 
diﬀ   erent conformations that vary in their aﬃ   nity  for 
ligands depending on the nature of both the extracellular 
and the intracellular stimuli [11,12]. Indeed, integrins not 
only send signals to the cell in response to extracellular 
guidance cues, such as chemokines or growth factors – a 
process called “outside-in” signaling [12] – but they also 
respond to intracellular signals and alter the way they 
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© 2011 BioMed Central Ltdinter  act with the extracellular environment [13]. Th  ese 
intra  cellular signals can regulate integrin receptor 
adhesive  ness by modulating the conformations and the 
degree of binding to ECM ligands, regulating, for 
instance, cell migration and growth [11]. Th   is is generally 
referred to as “inside-out” signaling and notably involves 
crosstalk between receptor tyrosine kinase or G-protein-
coupled receptor signaling pathways and integrins [14,15] 
. Another signiﬁ    cant level of regulation of cell adhesion 
and migra  tion on ECM protein ligands involves the 
modulation of integrin endocytosis and recycling to the 
plasma membrane [16].
In the present review we will focus on β1-integrins, 
which constitute the largest subgroup of integrins, since 
the β1-subunit can form heterodimers with the most 
diﬀ  erent α-subunits (at least 12). After a description of its 
role in normal mammary gland development and its 
status in the pathological gland, we will emphasize the 
contribution of transgenic mouse models in highlighting 
how crucial β1-integrin appears to be for breast cancer 
progression.
β1-integrin signaling and mammary gland 
development
Whereas many subunits occur in only a single integrin 
heterodimer, the β1-subunit is found in 12 diﬀ  erent 
integrins (Figure 1) that all bind to ECM protein ligands, 
namely collagen, laminin, ﬁ   bronectin, tenascin C and 
vitronectin [17,18]. β1-integrins are expressed in a wide 
variety of tissues and diﬀ  erent cell types throughout the 
body. Th   ey are critical in the induction and maintenance 
of cell diﬀ  erentiation and are involved in various physio-
logical functions and in tissue homeostasis [17]. β1-
integrin has thus been shown critical for cartilage and 
bone formation [19], skeletal muscle development [20,21], 
epidermis formation [22], development of the cerebral 
cortex [23] and angiogenesis [24]. Accordingly, knockout 
studies have revealed an essential role for β1-integrin in 
early development, its genetic deletion resulting in 
embryonic lethality shortly after implantation, between 
embryonic days 6.5 and 7.5 [25-27].
β1-integrin signaling: a crucial role for the focal adhesion 
kinase axis
β1-integrin has been shown to bind directly or indirectly 
via its cytoplasmic domain to a substantial number of 
proteins [8,28]. Since integrins lack enzymatic activity and 
an actin binding domain, they must bind to partners that 
will support cytoskeleton remodeling and activation of 
downstream signaling cascades pathways involved in, for 
example, cell proliferation. Some of these proteins, like 
talin, kindlins, ﬁ  lamin, α-actinin, tensin, integrin cyto-
plasmic domain-associated protein-1, integrin-linked 
kinase, 14-3-3β and CD98, couple β1-integrins to the 
actin cytoskeleton and/or are involved in β1-integrin-
mediated cell adhesion and motility. Others, such as focal 
adhesion kinase (FAK), paxillin, receptor of activated 
kinase-1 or the Src family kinases yes and lyn, function as 
scaﬀ  olding and/or catalytic adaptors that allow activation 
of signaling pathways from adhesion sites to intracellular 
eﬀ  ectors [28-30].
Interestingly, some of these integrin-associated adap-
tors such as FAK, which is considered a central player in 
integrin-mediated signaling [31], show a crossover 
functionality. Integrin clustering elicits FAK activation 
and localization to focal adhesions. Two NXXY motifs 
present in the C-terminal of β1-integrin have been shown 
to be critical to its ability to recruit FAK and induce its 
autophosphorylation on Y397 [32]. FAK can then contri-
bute to integrin signaling in diﬀ  erent ways. As a tyrosine 
kinase, FAK phosphorylates substrates such as paxillin, a 
multidomain adaptor that can also be directly bound to 
β1-integrin [33]. However, paxillin can only become 
phosphorylated by FAK when it associates with the 
kinase through an interaction between its LD motifs and 
FAK’s carboxy terminal focal adhesion targeting domain 
[34,35].
Another role of FAK lies in its ability to form inter-
actions with other signaling molecules and thus to act as 
a scaﬀ   old protein recruiting several adaptors to focal 
adhesion sites [31]. Indeed, FAK autophosphorylation at 
Y397 promotes recruitment of c-Src, which in turn can 
phosphorylate FAK on various tyrosine residues that act 
as docking sites for a number of SH2 domain-containing 
signaling adaptors, facilitating the activation of a diverse 
range of signaling pathways [36,37]. For instance, Grb2 
binding to phos  phorylated Y925 activates a signaling 
Figure 1. β1-integrins constitute the largest subgroup of 
integrins. β1-integrin subunits can associate with 12 diff  erent 
α-subunits. All β1-integrins bind to extracellular matrix molecules. 
Shaded circles represent the α-subunits expressed in the mammary 
gland.
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factor expres  sion [38], and p85-PI3K regulatory sub  unit 
binding to the initially phosphorylated Y397 induces 
AKT activation and promotes cell survival [39]. FAK also 
contains proline-rich domains that mediate interactions 
with SH3 domain-containing proteins such as the multi-
adaptor Crk-associated substrate (p130Cas) or the 
GTPase regulator associated with FAK. Once phosphory-
lated by FAK-recruited c-Src, p130CAS is essential, for 
example, to recruit the Crk-Dock180 complex and 
activate Rac, thereby inducing migration [40] or the 
activation of a Ras/Rac/Pak1/JNK survival pathway [41].
β1-integrin in the mammary gland
In the normal mammary gland, interaction between 
epithelial cells and with the underlying BM is required 
for structural and functional integrity of the ductal 
component of the gland. Th   e breast ductal architecture is 
indeed comprised of a bilayer of luminal epithelial and 
basal myoepithelial cells, which remain separated from 
the stroma by the BM. Th  e myoepithelial layer limits 
contact between luminal cells and the BM. In the alveoli 
(the milk-secreting units), however, luminal cells can 
directly interact with the BM between the processes of 
the stretched myoepithelial cells [18]. Integrins are pre-
dominantly expressed in the basal cell layer of the 
mammary epithelium in comparison with the luminal 
compartment. Owing to their direct interactions with 
ECM ligands, β1-integrins play a critical role in the main-
tenance of mammary tissue integrity [18]. In addition, 
they are essential for the control of cell survival and 
proliferation during mammary gland development as 
well as for mammary epithelial cell diﬀ  erentiation [42-
44]. Moreover, β1-integrin expression has been revealed 
as necessary for maintenance of functional mammary 
stem cells, which are part of the basal compartment, 
allowing mammary morphogenesis and segregation of 
the two mammary ductal compartments [45,46]. Inte-
grins expressed on breast epithelial cells include β1-
integrin-containing and β4-integrin-containing hetero-
dimers (Figure 2) [18,45,47]. α6β4-integrin has a role in 
maintaining epi  thelial integrity based on its ability to 
mediate formation of hemidesmosomes that link the 
intermediate cyto  keratin ﬁ   lament network of the 
mammary cells to ECM laminins [48].
Mammary β1-integrins, consisting of α1β1, α2β1, α3β1, 
α5β1 and α6β1, present a more heterogeneous localiza-
tion and role. Th   ey are present at sites of cell–ECM inter-
action both on myoepithelial cells and alveolar luminal 
cells. Luminal epithelial cells also express the α2β1, α3β1, 
and α6β1 heterodimers at cell–cell junctions, however, 
while α1β1 and α5β1 seem to be exclusively expressed in 
the myoepithelium (Figure 2) [18]. Although highest ex-
pres  sion of the α5β1-integrin was found in myoepi  thelial 
cells, luminal cells in contact with the BM can also stain 
strongly for α5β1 [49]. An in vitro study suggests that β1-
integrins can have a signiﬁ   cant impact on hor  monal 
control of mammary development by controlling, for 
example, expression of estrogen receptor α [50]. 
Reciprocally, ovarian steroids like estrogen and proges-
terone have been shown in vivo to regulate mammary 
gland expression of α5β1-integrin during puberty and 
sexual maturation [49].
In vivo evidence for a role of these integrins in 
mammary gland development came from studies using a 
gene deletion approach. Murine mammary glands 
formed from either α1-integrin-null, α3-integrin-null, 
α6-integrin-null or β4-integrin-null epithelia are thus 
fully developed and functional [51,52]. Th   e only integrin 
subunits so far shown to be indispensible for appropriate 
mammary gland development are α2 and β1 [43,44,53]. 
Although fertile and capable of lactating, mice deﬁ  cient 
in α2-integrin show a marked decrease in mammary 
ductal branching [53]. Th  e conditional deletion of β1-
integrin using targeted Cre recombinase expression in 
the luminal cell population after pubertal development 
and during later stages of diﬀ  erentiation (i.e., pregnancy 
and/or lactation) using β-lactoglobulin and whey acidic 
protein promoters, respectively, aﬀ  ects  alveologenesis 
and lactation due to an inhibition of mammary epithelial 
cell proliferation and diﬀ  erentiation [43,44]. Moreover, 
the ablation of β1-integrin from the basal cell layer of the 
mammary epi  thelium using Cre under control of the 
keratin 5 pro  moter impairs ductal branching as well as 
lobulo  alveolar morphogenesis in pregnancy, presumably 
because of disruption of the basal cell interactions with 
the ECM and disruption of stem cell renewal [46]. It is 
worth noting that in a model using the mouse mammary 
tumor virus (MMTV) promoter-driven Cre recombinase, 
where Cre is exclusively expressed in mammary luminal 
epithelial cells from 3 weeks of age [46,54], ablation of 
β1-integrin expression does not interfere with the initial 
stages of mammary ductal outgrowth [55].
Figure 2. Schematic representation of the diff  erent integrin 
heterodimers expressed in mammary epithelial cells. In the 
mammary ducts, most integrins are concentrated at sites of contact 
between the mammary basement membrane and myoepithelial 
cells. However, luminal epithelial cells also express the α2β1, α3β1, 
α6β1 and α6β4 heterodimers at cell–cell junctions.
2β β1 3β β1 luminal epithelial cells α α2β1
myoepithelial cells
mammary 
basement membrane
α3β1
α6β1
α1β1
α6β4
α5β1
α6β1 α3β1
α2β1 α6β4
basement membrane
Lahlou and Muller Breast Cancer Research 2011, 13:229 
http://breast-cancer-research.com/content/13/6/229
Page 3 of 10β1-containing integrin receptors are involved in 
human breast cancer progression
In the early 1990s several studies using human breast 
cancer samples revealed an aberrant expression of β1-
integrin. Either assayed by immunohistochemistry on 
frozen sections [56-59] or by in situ hybridization tech-
niques [60], β1-integrin expression has been found to be 
generally heterogeneous but also altered in 30 to 50% of 
breast cancers. Th  is observation was conﬁ  rmed in later 
investigations [61,62]. Many of these studies scored β1-
integrin expression based on a comparison with staining 
seen in normal tissues (i.e., concentrated at the BM, in 
the myoepithelial layer), and therefore possibly inaccu-
rately reported a decrease of or a loss of expression [56, 
58,  62]. Indeed, in invasive carcinomas this cell layer is 
most often absent and the expression of integrins on the 
surface of carcinoma cells is diﬀ  use.  Th  is expression 
pattern may thus have led to the erroneous assumption 
that there is an overall decrease in β1-integrin [47]. From 
numerous in vitro studies using human breast cancer cell 
lines, however, it is obvious that β1-integrin is not only 
expressed but is required for proliferation, survival and 
invasiveness of the transformed cells [63-65]. Never  the-
less, in this context, whether the regulation of β1-integrin 
overexpression is transcriptional, translational or post-
translational is not known.
In the same way, studies to associate β1-integrin 
expression in breast cancer with patient survival gave 
contradictory conclusions. While a trend was seen towards 
poorer survival of patients with tumors with absent or 
weak expression of β1-integrin in a study of 55 cases [62], 
a lack of any diﬀ  erence in the survival curves for presence 
or absence of staining for β1-integrin was reported in 
another study involving 99 patients [61]. More recently, 
Yao and colleagues reported that an increased β1-
integrin level, which was also linked to the level of its 
ligand ﬁ   bronectin, was associated with signiﬁ  cantly 
decreased 10-year overall survival and recurrence-free 
survival in a cohort of 149 patients with early-stage 
invasive breast cancer [66]. Interestingly, neither estrogen 
receptor expression nor progesterone receptor expression 
was signiﬁ  cant with respect to β1-integrin overexpression 
or overall or disease-free survival [66]. In agreement with 
this, Lesniak and colleagues did not ﬁ  nd any signiﬁ  cant 
correlation between β1-integrin expression and prog-
nostic factors such as estrogen receptor and progesterone 
receptor in a study involving 113 patients with human 
epidermal growth factor receptor 2 (HER2)-positive 
metastatic breast cancer [67]. In contrast, a strong signi-
ﬁ  cant association was found between β1-integrin over-
expression and short time to tumor progression in women 
treated with trastuzumab-based chemotherapy [67].
Studies reporting activation and elevated expression of 
β1-integrin signaling eﬀ  ectors in human breast cancers 
strengthen a potential role of this integrin as a prognostic 
marker. A large proportion of primary human breast 
cancers possess elevated FAK expression that is further 
correlated with malignant transformation and poor 
clinical outcome [68,69]. Paxillin expression was found to 
be correlated with HER2 overexpression in an immuno-
histochemistry study of 314 primary invasive breast 
carcinomas [70], and BCAR1/p130Cas protein levels 
were found to be inversely related with relapse-free 
survival and overall survival as assessed by ELISA on 
2,593 primary breast tumor cytosols [71].
Genetic ablation of β1-integrin in transgenic mice 
reveals a critical role in mammary tumor initiation, 
metastasis and dormancy
Despite an ostensible role for β1-integrin in mammary 
gland development, the involvement of this particular 
integrin in breast cancer initiation and progression has 
only recently been demonstrated. Th   is has been permitted 
by the use of engineered murine models of human breast 
cancers where β1-integrin expression has been speciﬁ  cally 
disrupted in the mammary luminal epithelium.
β1-integrin in PyVmT-induced tumorigenesis
Th  e  ﬁ  rst study directly underlining an in vivo role for β1-
integrin in mammary tumorigenesis was performed 
using the polyoma virus middle T antigen (PyVmT) 
mouse model of breast cancer [55]. A conditional β1-
integrin allele (that is, LoxP1 ﬂ  anked) was introduced 
into transgenic mice expressing the PyVmT oncogene 
and Cre both under the control of the MMTV promoter/
enhancer [55]. Th   e PyVmT mouse model of breast cancer 
is extensively used to study mammary tumorigenesis. 
Th  is model recapitulates the stages of human disease 
since it evolves through four distinctly identiﬁ  able stages 
of tumor progression, from premalignant to invasive [72]. 
Aside from exhibiting a rapid onset and a high rate of 
metastasis to the lung, the MMTV-PyVmT mammary 
tumor model presents the advantage of reﬂ  ecting  the 
downstream signaling pathways triggered by the HER2 
oncogene involving activation of critical cancer-related 
molecules such as c-Src, the p85-PI3K regulatory subunit 
or Ras [73].
Using targeted excision of β1-integrin in luminal 
epithelial cells where the PyVmT oncogene was expressed 
[55], we have shown that β1-integrin was absolutely 
required for the induction of mammary tumors. Indeed, 
all tumors that arose in the MMTV-Cre/MMTV-
PyVmt;β1 LoxP1 animals were populated by cells retain-
ing expression of β1-integrin and lacking Cre expression. 
Th   is was pro  posed to be the result of a selective pressure 
against MMTV-Cre expression in mammary luminal 
epithelial cells undergoing PyVmT-driven transformation 
[55]. In addition, in vitro data using primary cultured 
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expressing adenoviruses have shown that ablation of β1-
integrin in mammary tumor cells is associated with a 
proliferative block and a disruption in FAK activation and 
subcellular localization [55]. Interestingly, although 
PyVmT tumor cells lacking β1-integrin were unable to 
proliferate, they failed to exhibit any evidence of 
apoptotic cell death. In fact, viable quiescent tumor cells 
lacking β1-integrin could be detected even 8 weeks after 
transplantation into cleared mammary fat pads of 
syngeneic recipient mice. Th  e presence of β1-integrin-
null tumor cells that are unable to proliferate but still 
retain viability exhibits a striking resemblance to the 
phenomenon of tumor dormancy [55,74]. Overall, this 
work has provided evidence that β1-integrin expression 
is required for the initial stages as well as for the 
maintenance of advanced stages of PyVmT-induced 
mammary tumorigenesis.
Consistent with these analyses, four independent studies 
evaluating the loss of function of the β1-integrin signaling 
partner FAK in the MMTV-PyVmT mouse model have 
demonstrated a critical role for this kinase in initiation 
and/or progression of mammary tumorigenesis [54,75-
77]. At ﬁ  rst, using an approach identical to the afore-
mentioned, mammary epithelial disruption of FAK was 
demonstrated to result in a dramatic reduction in the 
proliferative potential of PyVmT-transformed cells with-
out exhibiting evidence of enhanced apoptosis. Impor-
tantly, these results demonstrate that although FAK is 
dispensable for the initiation of mammary tumorigenesis, 
it is still required for the transition of premalignant 
hyper  plasias to carcinomas and their subsequent meta-
stases [54]. Th  is dramatic result was subsequently con-
ﬁ  rmed by a number of independent laboratories [75-77]. 
One of these studies suggested that the block in PyVmT 
tumor progression was due to the reduction of the pool 
of cancer stem/progenitor cells [75]. Collectively, these 
studies argue that FAK plays a critical role in PyVmT-
mediated tumorigenesis and support the in vivo data 
establishing β1-integrin as a crucial player in mammary 
tumor progression.
β1-integrin in ErbB2-induced tumorigenesis
Ampliﬁ   cation and overexpression of ErbB2/HER2, a 
member of the epidermal growth factor receptor (EGFR) 
family, is observed in 25 to 30% of sporadic breast cancers 
and is inversely correlated with the survival of the patient 
[78]. Direct evidence indicating that ErbB2 acts as a 
mammary oncogene derives from initial studies of trans-
genic mice expressing an activated Neu (the rat homolog 
of ErbB2) under the transcriptional control of the MMTV 
promoter [79].
Recently, in the context of this mouse model, the role of 
β1-integrin in ErbB2-induced mammary tumor 
progres  sion was investigated by utilizing the same 
conditional β1-integrin strain we previously crossed to 
the PyVmT model of breast cancer [55]. One compli-
cation en  countered with the MMTV-Cre mouse line we 
initially used is the stochastic expression of the Cre trans-
gene ranging from 50 to 80% of the luminal epithelial 
cells. Moreover, we estimated the overall proportion of 
Cre nonexpressing cells at approximately one-third 
[54,55]. Cre-negative mammary epithelial cells thus 
retain expression of the conditional allele and are 
selectively targeted for oncogenic transformation [54,55]. 
To circum  vent the selective pressure against the Cre-
positive/β1-negative cells undergoing transformation, we 
have crossed the conditional β1-integrin strain to the 
MMTV-NIC strain [80,81]. Th  ese mice coexpress both 
an activated ErbB2 and the Cre recombinase from the 
same bicistronic transcript due to the presence of an 
internal ribosome entry site between the two cDNA 
sequences [80,81]. Expression of activated ErbB2 and Cre 
is hence coupled within the luminal epithelial cell, pre-
cluding the possibility of obtaining ErbB2 oncogene-
expressing/Cre-negative “escapee” transformed cells. In 
contrast to the complete block in PyVmT-induced 
tumorigenesis [55], mammary epithelial disruption of β1-
integrin did not prevent ErbB2-mediated tumor induc-
tion [80]. Although a signiﬁ  cant 33-day delay in tumor 
onset was observed, all of the mice developed mammary 
tumors histologically similar to their control counterparts 
[80]. Nevertheless, quantiﬁ  cation of both the penetrance 
and the extent of lung metastasis in the β1-integrin-
deﬁ   cient mice revealed that loss of this integrin was 
associated with a twofold reduction in the number of 
mice that developed meta  stases and with a sixfold 
reduction in the average metastatic burden compared 
with β1-integrin-proﬁ  cient controls. Th  ere  fore,  although 
β1-integrin is not required for ErbB2-mediated 
mammary tumor initiation and progression, it does play 
a major role in the subsequent metastatic phase of 
tumorigenesis in the MMTV-Neu-NDL2-5 model [80].
Interestingly, examination of the β1-integrin-deﬁ  cient 
mammary tumors revealed a reduction in both tumor 
cell survival and angiogenic inﬁ  ltration. Th   is later eﬀ  ect 
has been shown to be cell autonomous, as demonstrated 
by transplantation into the fat pads of immunodeﬁ  cient 
mice and quantiﬁ   cation of CD31-positive vessels [80]. 
Moreover, analysis of the activation state of numerous 
integrin-coupled signaling partners using phospho  tyro-
sine-speciﬁ   c antibodies indicated that β1-integrin-
deﬁ   cient tumors exhibited a decrease in c-Src, FAK, 
p130Cas and paxillin phosphorylation, possibly indicat-
ing a defect in adhesion responsible for the reduced 
metastatic potential of Neu mammary tumor cells lacking 
β1-integrin [80]. Another striking molecular eﬀ  ect of β1-
integrin deletion was a remarkable decrease in EGFR 
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tumors when compared with control samples [80]. 
Indeed, an important function of β1-integrin signaling is 
its capacity to transphosphorylate EGFR and to cooperate 
with this receptor in the control of cell proliferation, 
adhesion and migration [82]. β1-integrin–EGFR crosstalk 
and transactivation have also been implicated in the 
endocytic recycling of these two receptors. Particularly, 
the enhanced migration of human ovarian carcinoma 
cells has been shown to involve Rab-coupling protein-
dependent recycling of α5β1-integrin and coordination 
of its traﬃ   cking with that of EGFR [83]. Furthermore, 
α5β1-integrin–EGFR inter  action has been reported to 
contribute to the invasive phenotype of human prostate 
cancer cells through the formation of a urokinase-type 
plasminogen activator receptor/α5β1-integrin/EGFR 
ternary complex [84]. Th   e profound defect in metastasis 
observed in β1-integrin-deﬁ  cient MMTV-Neu mice may 
thus be the result of altered recycling of EGFR and/or 
disruption of EGFR-coupled signaling pathways involved 
in cell invasion.
Finally, analyses revealed that the α6-integrin and β4-
integrin subunits were downregulated upon disruption of 
β1-integrin [80]. α6β4-integrin has been associated with 
reduced survival and poor prognosis in breast cancer 
[85]. Moreover, in vitro its activation has been implicated 
in breast carcinoma progression [86]. Interestingly, 
antibody-mediated crosslinking of α6β4-integrin has 
been shown to induce breast carcinoma cell-surface 
clustering of EGFR and to promote Rho activation in 
response to EGF, suggesting that α6β4-integrin–EGFR 
crosstalk may facilitate tumor cell cytoskeletal rearrange-
ments important for tumor progression [87]. Th  erefore, 
together with the reduced phosphorylation of several β1-
integrin signaling partners, downregulation of both 
α6β4-integrin and EGFR presumably plays a decisive role 
in the impaired metastatic capacity of the β1-integrin-
deleted mammary tumor cells. Moreover, the β4-integrin 
downregulation observed consequently to β1-integrin 
conditional knockout is in agreement with in vivo 
analyses obtained on a MMTV-activated-Neu strain [88]. 
By introducing a targeted deletion of the β4-integrin 
signaling domain into a mouse model of ErbB2-induced 
mammary carcinoma, Guo and colleagues have shown 
that β4-integrin signaling is also critical for Neu-induced 
tumor progression [88]. In fact, the β4-integrin mutant 
transgenic mice presented phenotypes very similar to the 
conditional β1-integrin strain we developed. Loss of β4-
integrin signaling inhibits mammary tumor onset and 
initial growth by decreasing cell proliferation and 
increasing apoptotic rates, and inhibits tumor invasion 
and metastasis to the lungs [88]. Overall, unlike the 
PyVmT model in which β1-integrin is required for tumor 
initiation, β1-integrin seems to be primarily involved in 
the metastatic phase of tumor progression in the context 
of ErbB2-induced transformation.
It is interesting to note that targeted disruption of the 
β1-integrin eﬀ  ector integrin-linked kinase in the same 
ErbB2 mouse model was recently demonstrated to be 
associated with complete loss of p130Cas and paxillin 
tyrosine phosphorylation, and with impaired Neu-
induced tumor progression [89]. Moreover, by crossing 
MMTV-p130Cas and MMTV-Neu mice, Cabodi and 
colleagues generated double-transgenic mice with an 
accelerated onset of mammary tumor formation. Th  e 
subsequent tumors exhibited increased activation of Src 
and Akt pathways, suggesting a role for the p130Cas 
adaptor as a positive regulator of both cell proliferation 
and cell survival induced by the Neu proto-oncogene 
[90]. Th  ese data further argue that β1-integrin – as 
opposed to β3-integrin and β5-integrin, which have been 
shown to be dispensable for Neu-induced tumor growth 
[91] – favors ErbB2-mediated tumor progression.
β1-integrin as a potential therapeutic target
Given the accumulation of in vivo evidence, it is tempting 
to claim that β1-integrin shows interesting therapeutic 
potential as a target for the treatment of human breast 
cancer. However, as pointed out earlier, because of 
conﬂ   icting studies [61,62,66], expression of the β1-
subunit alone cannot be clearly accepted as a useful 
prognostic indicator in patients with breast cancer. 
Although inhibitory antibodies directed against β1-
integrin (notably clone AIIB2) have already been shown 
to be eﬀ  ective in reverting the tumorigenic phenotype of 
breast cancer cell lines [64,65], strategies to target the β1-
integrin subunit for therapy (Table 1) have not progressed 
rapidly, presumably because of the heterogeneity of the 
β1 subgroup of integrins. Indeed, the β1-subunit can 
form heterodimers with at least 12 diﬀ  erent α-subunits 
(Figure 1). In mammary ducts, this β1-subunit is found in 
heterodimers with α1, α2, α3, α5 and α6, hence mediating 
adhesion to a number of diﬀ  erent ECM ligands including 
collagen, laminin and ﬁ  bronectin [18].
A recently published work was the ﬁ   rst to deﬁ  ne  a 
speciﬁ  c role for a single αβ1 heterodimer in mammary 
tumor progression [92]. To do so, the authors crossed α2-
integrin-null transgenic animals [53] with MMTV-Neu 
mice to generate animals expressing an oncogenic ErbB2 
in α2β1-integrin-deﬁ   cient mammary epithelium [92]. 
Since α2β1-integrin has been shown to mediate hepatic 
metastasis [93], it was surprising to observe that loss of 
the α2β1-integrin not only (even modestly) reduces 
mammary tumor latency in MMTV-Neu mice but 
markedly increases metastasis to the lungs [92]. Although 
a role for α2β1-integrin in the tumor microenvironment 
cannot be excluded in this model, in vitro experiments 
performed on primary cultured epithelial tumor cells 
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enhanced tumor cell migration, intravasation and 
anchorage-independent growth [92]. More  over, analysis 
of gene expression proﬁ  ling data established a correlation 
between loss of α2β1-integrin expression and metastasis 
and decreased survival in breast cancer patients [92]. 
Deleting the α2-integrin subunit, hence precluding α2β1-
integrin heterodimer expression, has thus revealed 
antagonistic eﬀ   ects in Neu-driven mammary cancer 
progression compared with deleting the β1-subunit and 
thus all of the β1 hetero  dimers. Under  standing the role 
and inﬂ  uence of each speciﬁ  c hetero  dimer in mammary 
tumorigenesis might be essential to develop a more 
selective therapeutic approach. Although this constitutes 
a major challenge, the diversity of β1-integrin hetero-
dimers in mammary tissue still provides great oppor-
tunities for drug development [10,94].
For example, strategies developed against the α5β1 
heterodimer, an integrin expressed on the basal surface 
of myoepithelial mammary ductal cells, led to the 
development of a rat-anti-mouse blocking antibody able 
to inhibit the growth of established tumors in multiple 
xenograft models [95]. Volociximab, another blocking 
antibody against α5β1-integrin that is currently in 
multiple phase II clinical trials, including as monotherapy 
in patients with platinum-resistant advanced epithelial 
ovarian cancer or primary peritoneal cancer [96], was 
found to signiﬁ   cantly inhibit tumor growth when ad-
minis  tered intravenously in the rabbit VX2 carcinoma 
model [97]. ATN-161, an integrin-binding peptide inhibi-
tor that is currently in phase II trials in cancer patients, 
represents another α5β1 therapeutic strategy [98]. In a 
MDA-MB-231 human breast cancer cell xenograft model, 
treatment with ATN-161 caused a signiﬁ  cant decrease in 
both tumor growth and metastasis [99]. Furthermore, the 
combination of ATN-161 and ﬂ  uorouracil  reduced 
colorectal liver metastases and improved survival in mice 
compared with either therapeutic alone [100]. Other 
inhibitors targeting β1-integrins have been developed, 
particularly nonpeptide inhibitors of α4β1-integrin, and 
are in phase II clinical trials as candidate drugs for 
asthma, multiple sclerosis, or ulcerative colitis [94]. It 
would be interesting to test these drugs in preclinical 
models of breast cancer.
Another attractive aspect of targeting β1-integrins 
comes from the fact that their inhibition can potentiate 
eﬃ   ciency of existing treatments (Table 1). By combining 
the β1-integrin blocking antibody AIIB2 and trastuzumab 
in HER-2-positive cells known to be sensitive to trastuzu-
mab (SKBR-3 and BT-474) or resistant to trastuzumab 
(JIMT-1), Lesniak and colleagues observed that conco-
mitant inhibition of β1-integrin and HER-2 synergis-
tically increased the cytotoxic or antiproliferative eﬀ  ects 
of trastuzumab and preferentially suppressed the survival 
or growth of HER-2-positive cells overexpressing β1-
integrin [67]. Also, AIIB2 has been shown to synergize 
with ionizing radiation to signiﬁ   cantly decrease AKT-
mediated ionizing radiation resistance of breast cancer 
cell lines. In vivo, addition of AIIB2 after ionizing 
radiation signiﬁ  cantly enhanced tumor growth inhibition 
and apoptosis compared with either treatment alone in a 
breast cancer xenograft model [101,102]. Th  ese data 
provide great expectations of enhanced radiation therapy 
in breast cancer.
Table 1. β1-integrin inhibitors currently in preclinical or clinical development for cancer therapy
 Type  of     
Drug or treatment  therapeutic agent  Stage  Target  Tumor model  Reference
Clone AIIB2  Rat IgG1 mAb  Preclinical  β1-subunit  MCF-7 human breast cancer xenograft  [64]
Clone AIIB2 + ionizing  Rat IgG1 mAb +   Preclinical  β1-subunit  MCF-7 human breast cancer xenograft  [102]
radiation radiotherapy
Clone 339.1   Rat IgG1 mAb  Preclinical  α5β1  SVR murine angiosarcoma and A673 human   [95]
       rhabdomyosarcoma  xenografts
Volociximab  Chimeric (82% human/  Preclinical  α5β1  Rabbit VX2 carcinoma model  [97]
  18% murine) IgG4 mAb
    Phase I  α5β1  Patients with advanced solid malignancies  [105]
    Phase II  α5β1  Patients with platinum-resistant advanced   [96]
        epithelial ovarian cancer or primary peritoneal cancer
ATN-161  Small peptide  Preclinical  α5β1  MDA-MB-231 human breast xenograft and skeletal   [99]
 antagonist      metastasis
    Preclinical  α5β1  Lewis lung adenocarcinoma model  [98]
    Phase I  α5β1  Patients with advanced solid malignancies  [106]
ATN-161 + 5-fl  uorouracil  Small peptide antagonist +  Preclinical  α5β1  CT26 murine colorectal liver metastasis  [100]
 chemotherapy
mAb, monoclonal antibody.
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Taken together, the above data reveal that β1-integrins 
(as well as some of their signaling partners) may represent 
attractive therapeutic targets for the treatment of primary 
breast cancer. Th  e use of transgenic mouse models of 
breast cancer (that is, MMTV-PyVmT and MMTV-
activated ErbB2) has provided direct in vivo evidence for 
the importance of β1-integrins in mammary tumor 
progression. Notwithstanding, one may have reservations 
about the models utilized [4,73]. Indeed, one limitation 
of these transgenic mouse models is that expression of 
the oncogene is driven by a strong viral promoter. Not 
only does MMTV drive high levels of transgene expres-
sion, but it integrates totally randomly into the mouse 
genome [79,103]. Th  e use of the ErbB2 knockin model 
[79,104], where the Cre-inducible expression of activated 
ErbB2 is under the transcriptional control of the endo  ge-
nous ErbB2 promoter, would provide even more repre-
sen  tative insights into the role of β1-integrin in breast 
cancer progression. Remarkably, this unique model 
presents aspects very similar to the human pathology: 
ampliﬁ  cation of erbB2 and histological features of non-
invasive ductal carcinoma in situ [73]. Nonetheless, the 
in vivo data so far collected highlight the crucial role of 
β1-integrin in mammary tumor progression, in particular 
in its metastatic phase, and are of great clinical interest, 
given that metastasis still represents the leading cause of 
death in breast cancer patients.
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